US 6,982,075 B2
Use of pulmonary surfactant
Friedemann Taut, Constance (Germany)
Assigned to Altana Pharma AG, Constance (Germany)
Appl. No. 10/491,961
PCT Filed Oct. 10, 2002, PCT No. PCT/EP02/11325
§ 371(c)(1), (2), (4) Date Apr. 08, 2004,
PCT Pub. No. WO03/033014, PCT Pub. Date Apr. 24, 2003.
Claims priority of application No. 01000531 (EP), filed on Oct. 11, 2001.
Prior Publication US 2004/0247529 A1, Dec. 09, 2004
Int. Cl. A61L 9/04 (2006.01)
U.S. Cl. 424—45 3 Claims
OG exemplary drawing
 
1. A method of treating a patient comprising administering a therapeutically effective amount of a pulmonary surfactant preparation to a patient in order to decrease a risk or side effect of toxic oxygen concentration, wherein the patient is artificially respirated and has a quotient of arterial oxygen partial pressure and inspiratory oxygen concentration (PaO2/FiO2) of 200 mmHg or lower, and
wherein the oxygen concentration of the gas employed for respiration is greater than or equal to 50% by volume.